{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:22:45Z","timestamp":1747207365206,"version":"3.40.5"},"reference-count":160,"publisher":"Bentham Science Publishers Ltd.","issue":"13","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDM"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>The kidneys are vital organs acting as the body\u2019s filters that eliminate drugs and other waste products from the body. For effective cancer therapy, a delicate balance is required in the drug treatment and its elimination, which is critical for drug accumulation, toxicity, and kidney malfunction. However, how renal cell carcinoma (RCC) affects the kidneys in safely eliminating the byproducts of drug treatments in patients with severely dysregulated kidney functions had remained elusive. Recent advancements in dose adjustment have added to our understanding regarding how drug treatments could be effectively regulated in aberrant kidney cells, driving safe elimination and reducing drug accumulation and toxicity at the right time and space. Dose adjustment is the only standard systemic way applicable; however, it presents certain limitations. There is significant room for developing new strategies and alternatives to improve it.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives:<\/jats:title><jats:p>Our analysis of the available treatments in literature discusses the treatment and their safe eliminations. In this study, we give an overview of the measures that could be taken to maintain the elimination gradient of anti-cancer drugs and restore normal kidney function in RCC. Differential therapeutics of RCC\/mRCC in various clinical phase trials and the interaction of targeted therapeutics in response to vascular endothelial growth factor (VEGF) were also discussed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Such information might suggest a new direction in controlling treatment with safe elimination through dose adjustment and its associated alternatives in a judicious manner. A strategy to systematically focus on the safe elimination of anti-cancer drugs in RCC strongly needs advocating.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1389200221666201112112707","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T04:31:53Z","timestamp":1605241913000},"page":"1009-1021","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Concomitant Drug Treatment and Elimination in the RCC-affected Kidneys: Can We Kill Two Birds with One Stone?"],"prefix":"10.2174","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6816-4779","authenticated-orcid":true,"given":"Muhammad Bilal","family":"Ahmed","sequence":"first","affiliation":[{"name":"School of Life Sciences, College of Natural Sciences, Kyungpook National University, Daegu, 41566,Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6692-0270","authenticated-orcid":true,"family":"Salman Ul Islam","sequence":"additional","affiliation":[{"name":"School of Life Sciences, College of Natural Sciences, Kyungpook National University, Daegu, 41566,Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5841-6506","authenticated-orcid":true,"given":"Young Sup","family":"Lee","sequence":"additional","affiliation":[{"name":"School of Life Sciences, College of Natural Sciences, Kyungpook National University, Daegu, 41566,Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1542\/peds.108.3.776","volume":"108","year":"2001","unstructured":"American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001,108(3),776-789","journal-title":"Pediatrics"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/1523-1747.ep12260784","volume":"56","author":"Johnson H.L.","year":"1971","unstructured":"Johnson H.L.; Maibach H.I.; Drug excretion in human eccrine sweat. J Invest Dermatol 1971,56(3),182-188","journal-title":"J Invest Dermatol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.jsps.2016.10.002","volume":"25","author":"Idkaidek N.M.","year":"2017","unstructured":"Idkaidek N.M.; Comparative assessment of saliva and plasma for drug bioavailability and bioequivalence studies in humans. Saudi Pharm J 2017,25(5),671-675","journal-title":"Saudi Pharm J"},{"key":"ref=4","first-page":"285","volume":"2","author":"Stoller R.G.","year":"1976","unstructured":"Stoller R.G.; Jacobs S.A.; Drake J.C.; Lutz R.J.; Chabner B.A.; Pharmacokinetics of high-dose methotrexate (NSC-740). Report of the Division of Cancer Treatment J Natl Cancer Inst 1976,2,285","journal-title":"J Natl Cancer Inst"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/BF00686147","volume":"31","author":"Pfl&#xFC;ger K-H.","year":"1993","unstructured":"Pfl&#xFC;ger K-H.; Hahn M.; Holz J-B.; Schmidt L.; K&#xF6;hl P.; Fritsch H-W.; Jungclas H.; Havemann K.; Pharmacokinetics of etoposide: correlation of pharmacokinetic parameters with clinical conditions. Cancer Chemother Pharmacol 1993,31(5),350-356","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1200\/JCO.1996.14.12.3062","volume":"14","author":"O\u2019Reilly S.","year":"1996","unstructured":"O\u2019Reilly S.; Rowinsky E.K.; Slichenmyer W.; Donehower R.C.; Forastiere A.A.; Ettinger D.S.; Chen T.L.; Sartorius S.; Grochow L.B.; Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol 1996,14(12),3062-3073","journal-title":"J Clin Oncol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"461","DOI":"10.2165\/00003088-199121060-00006","volume":"21","author":"Jelliffe R.W.","year":"1991","unstructured":"Jelliffe R.W.; Iglesias T.; Hurst A.K.; Foo K.A.; Rodriguez J.; Individualising gentamicin dosage regimens. A comparative review of selected models, data fitting methods and monitoring strategies. Clin Pharmacokinet 1991,21(6),461-478","journal-title":"Clin Pharmacokinet"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev-pharmtox-011112-140317","volume":"53","author":"Morrissey K.M.","year":"2013","unstructured":"Morrissey K.M.; Stocker S.L.; Wittwer M.B.; Xu L.; Giacomini K.M.; Renal transporters in drug development. Annu Rev Pharmacol Toxicol 2013,53,503-529","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0344-0338(99)80088-0","volume":"195","author":"Val-Bernal J.F.","year":"1999","unstructured":"Val-Bernal J.F.; G&#xF3;mez-Rom&#xE1;n J.J.; Vallina T.; Villoria F.; Mayorga M.; Garc&#xED;a-Arranz P.; Papillary (chromophil) renal cell carcinoma with mucinous secretion. Pathol Res Pract 1999,195(1),11-17","journal-title":"Pathol Res Pract"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3389\/fgene.2019.00320","volume":"10","author":"Braga E.A.","year":"2019","unstructured":"Braga E.A.; Fridman M.V.; Loginov V.I.; Dmitriev A.A.; Morozov S.G.; Molecular mechanisms in clear cell renal cell carcinoma: role of miRNAs and hypermethylated miRNA genes in crucial oncogenic pathways and processes. Front Genet 2019,10,320","journal-title":"Front Genet"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","volume":"3","author":"Hsieh J.J.","year":"2017","unstructured":"Hsieh J.J.; Purdue M.P.; Signoretti S.; Swanton C.; Albiges L.; Schmidinger M.; Heng D.Y.; Larkin J.; Ficarra V.; Renal cell carcinoma. Nat Rev Dis Primers 2017,3,17009","journal-title":"Nat Rev Dis Primers"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/cncr.10255","volume":"94","author":"Delahunt B.","year":"2002","unstructured":"Delahunt B.; Kittelson J.M.; McCredie M.R.; Reeve A.E.; Stewart J.H.; Bilous A.M.; Prognostic importance of tumor size for localized conventional (clear cell) renal cell carcinoma: assessment of TNM T1 and T2 tumor categories and comparison with other prognostic parameters. Cancer 2002,94(3),658-664","journal-title":"Cancer"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"505.e9","DOI":"10.1016\/j.urolonc.2015.07.017","volume":"33","author":"Winters B.R.","year":"2015","unstructured":"Winters B.R.; Gore J.L.; Holt S.K.; Harper J.D.; Lin D.W.; Wright J.L.; Cystic renal cell carcinoma carries an excellent prognosis regardless of tumor size. Urol Oncol 2015,33(12),505.e9-505.e13","journal-title":"Urol Oncol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.2215\/CJN.02020309","volume":"4","author":"Bonsib S.M.","year":"2009","unstructured":"Bonsib S.M.; Renal cystic diseases and renal neoplasms: a mini-review. Clin J Am Soc Nephrol 2009,4(12),1998-2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=15","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.12.9414","volume":"201","author":"Jhaveri K.","year":"2013","unstructured":"Jhaveri K.; Gupta P.; Elmi A.; Flor L.; Moshonov H.; Evans A.; Jewett M.; Cystic renal cell carcinomas: do they grow, metastasize, or recur? AJR Am J Roentgenol 2013,201(2)","journal-title":"AJR Am J Roentgenol"},{"key":"ref=16","first-page":"776","volume":"40","author":"Rao K.","year":"2011","unstructured":"Rao K.; Royce P.L.; Incidentally detected small renal masses - investigation and management. Aust Fam Physician 2011,40(10),776-782","journal-title":"Aust Fam Physician"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1111\/j.1442-2042.2012.03079.x","volume":"19","author":"Vera-Badillo F.E.","year":"2012","unstructured":"Vera-Badillo F.E.; Conde E.; Duran I.; Chromophobe renal cell carcinoma: a review of an uncommon entity. Int J Urol 2012,19(10),894-900","journal-title":"Int J Urol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1148\/rg.266065010","volume":"26","author":"Prasad S.R.","year":"2006","unstructured":"Prasad S.R.; Humphrey P.A.; Catena J.R.; Narra V.R.; Srigley J.R.; Cortez A.D.; Dalrymple N.C.; Chintapalli K.N.; Common and uncommon histologic subtypes of renal cell carcinoma: imaging spectrum with pathologic correlation. Radiographics 2006,26(6),1795-1806","journal-title":"Radiographics"},{"key":"ref=19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11030422","volume":"11","author":"Pichler R.","year":"2019","unstructured":"Pichler R.; Comp&#xE9;rat E.; Klatte T.; Pichler M.; Loidl W.; Lusuardi L.; Schmidinger M.; Renal cell carcinoma with sarcomatoid features: finally new therapeutic hope? Cancers (Basel) 2019,11(3)","journal-title":"Cancers (Basel)"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/00000478-200103000-00001","volume":"25","author":"de Peralta-Venturina M.","year":"2001","unstructured":"de Peralta-Venturina M.; Moch H.; Amin M.; Tamboli P.; Hailemariam S.; Mihatsch M.; Javidan J.; Stricker H.; Ro J.Y.; Amin M.B.; Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol 2001,25(3),275-284","journal-title":"Am J Surg Pathol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/1097-0142(19870201)59:3<516::AID-CNCR2820590327>3.0.CO;2-W","volume":"59","author":"Ro J.Y.","year":"1987","unstructured":"Ro J.Y.; Ayala A.G.; Sella A.; Samuels M.L.; Swanson D.A.; Sarcomatoid renal cell carcinoma: clinicopathologic. A study of 42 cases. Cancer 1987,59(3),516-526","journal-title":"Cancer"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","volume":"70","author":"Moch H.","year":"2016","unstructured":"Moch H.; Cubilla A.L.; Humphrey P.A.; Reuter V.E.; Ulbright T.M.; The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur Urol 2016,70(1),93-105","journal-title":"Eur Urol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0022-5347(05)65384-0","volume":"167","author":"Mian B.M.","year":"2002","unstructured":"Mian B.M.; Bhadkamkar N.; Slaton J.W.; Pisters P.W.; Daliani D.; Swanson D.A.; Pisters L.L.; Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol 2002,167(1),65-70","journal-title":"J Urol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s00432-016-2304-3","volume":"143","author":"Gu L.","year":"2017","unstructured":"Gu L.; Li H.; Wang H.; Ma X.; Wang L.; Chen L.; Zhao W.; Zhang Y.; Zhang X.; Presence of sarcomatoid differentiation as a prognostic indicator for survival in surgically treated metastatic renal cell carcinoma. J Cancer Res Clin Oncol 2017,143(3),499-508","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref=25","first-page":"33","author":"Srigley J.","year":"2004","unstructured":"Srigley J.; WHO Classification of Tumours of the Urinaly System and Male Genital Organs Lyon: IARC, 2004,33-34","journal-title":"WHO Classification of Tumours of the Urinaly System and Male Genital Organs"},{"key":"ref=26","first-page":"1027","volume":"34","author":"Procopio G.","year":"2014","unstructured":"Procopio G.; Testa I.; Iacovelli R.; Grassi P.; Verzoni E.; Garanzini E.; Colecchia M.; Torelli T.; De Braud F.; Treatment of collecting duct carcinoma: current status and future perspectives. Anticancer Res 2014,34(2),1027-1030","journal-title":"Anticancer Res"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1097\/PAS.0b013e3182635954","volume":"36","author":"Gupta R.","year":"2012","unstructured":"Gupta R.; Billis A.; Shah R.B.; Moch H.; Osunkoya A.O.; Jochum W.; Hes O.; Bacchi C.E.; de Castro M.G.; Hansel D.E.; Zhou M.; Vankalakunti M.; Salles P.G.; Cabrera R.A.; Gown A.M.; Amin M.B.; Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship. Am J Surg Pathol 2012,36(9),1265-1278","journal-title":"Am J Surg Pathol"},{"key":"ref=28","first-page":"94","author":"Oyasu R","year":"2008","unstructured":"Oyasu R; Yang XJ; Yoshida O; Does granular cell type renal cell carcinoma exist? What are the features of clear cell renal cell carcinoma? What are the pathologic characteristics and the clinical implication of multilocular cystic renal cell carcinoma? In: Questions in Daily Urologic Practice: Updates for Urologists and Diagnostic Pathologists New York: Springer, 2008,94-7","journal-title":"Questions in Daily Urologic Practice: Updates for Urologists and Diagnostic Pathologists"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1590\/0100-3984.2013.1927","volume":"48","author":"Muglia V.F.","year":"2015","unstructured":"Muglia V.F.; Prando A.; Renal cell carcinoma: histological classification and correlation with imaging findings. Radiol Bras 2015,48(3),166-174","journal-title":"Radiol Bras"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1200\/JOP.2017.020909","volume":"13","author":"Beckermann K.E.","year":"2017","unstructured":"Beckermann K.E.; Sharma D.; Chaturvedi S.; Msaouel P.; Abboud M.R.; Allory Y.; Bourdeaut F.; Calderaro J.; de Cubas A.A.; Derebail V.K.; Hong A.L.; Naik R.P.; Malouf G.G.; Mullen E.A.; Reuter V.E.; Roberts C.W.M.; Walker C.L.; Wood C.G.; DeBaun M.R.; Van Poppel H.; Tannir N.M.; Rathmell W.K.; Renal Medullary Carcinoma: establishing standards in practice. J Oncol Pract 2017,13(7),414-421","journal-title":"J Oncol Pract"},{"key":"ref=31","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/5304324","volume":"2016","author":"Gonz&#xE1;lez-Serrano A.","year":"2016","unstructured":"Gonz&#xE1;lez-Serrano A.; Cortez-Betancourt R.; Al&#xED;as-Melgar A.; Botello-G&#xF3;mez P.J.; Ram&#xED;rez-Gardu&#xF1;o E.; Trujillo-V&#xE1;zquez E.I.; Torres-Santos Y.; Mata-Mart&#xED;nez J.A.; Carre&#xF1;o-de la Rosa F.; Multilocular cystic renal cell carcinoma or cystic nephrom? Case Rep Urol 2016,2016","journal-title":"Case Rep Urol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1309\/AH6FC77PYR2V6YAY","volume":"125","author":"Suzigan S.","year":"2006","unstructured":"Suzigan S.; L&#xF3;pez-Beltr&#xE1;n A.; Montironi R.; Drut R.; Romero A.; Hayashi T.; Gentili A.L.; Fonseca P.S.; deTorres I.; Billis A.; Japp L.C.; Bollito E.; Algaba F.; Requena-Tapias M.J.; Multilocular cystic renal cell carcinoma : a report of 45 cases of a kidney tumor of low malignant potential. Am J Clin Pathol 2006,125(2),217-222","journal-title":"Am J Clin Pathol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","volume":"70","author":"Moch H.","year":"2016","unstructured":"Moch H.; Cubilla A.L.; Humphrey P.A.; Reuter V.E.; Ulbright T.M.; The 2016 WHO classification of tumours of the urinary system and male genital organs\u2014part A: renal, penile, and testicular tumours. Eur Urol 2016,70(1),93-105","journal-title":"Eur Urol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1602\/neurorx.2.4.554","volume":"2","author":"Alavijeh M.S.","year":"2005","unstructured":"Alavijeh M.S.; Chishty M.; Qaiser M.Z.; Palmer A.M.; Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. NeuroRx 2005,2(4),554-571","journal-title":"NeuroRx"},{"key":"ref=35","first-page":"75","volume":"9","author":"Schilsky R.L.","year":"1982","unstructured":"Schilsky R.L.; Renal and metabolic toxicities of cancer chemotherapy. Semin Oncol 1982,9(1),75-83","journal-title":"Semin Oncol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/psb.1738","volume":"30","author":"Azhar A.","year":"2019","unstructured":"Azhar A.; Hussain K.; Majid A.; Drug management in patients with reduced kidney function. Prescriber 2019,30(2),18-22","journal-title":"Prescriber"},{"key":"ref=37","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000091","volume":"1","author":"Launay-Vacher V.","year":"2016","unstructured":"Launay-Vacher V.; Janus N.; Deray G.; Renal insufficiency and cancer treatments. ESMO Open 2016,1(4)","journal-title":"ESMO Open"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1146\/annurev.pharmtox.44.101802.121347","volume":"44","author":"Abdel-Rahman S.M.","year":"2004","unstructured":"Abdel-Rahman S.M.; Kauffman R.E.; The integration of pharmacokinetics and pharmacodynamics: understanding dose-response. Annu Rev Pharmacol Toxicol 2004,44,111-136","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/0002-9343(77)90397-7","volume":"62","author":"Levy G.","year":"1977","unstructured":"Levy G.; Pharmacokinetics in renal disease. Am J Med 1977,62(4),461-465","journal-title":"Am J Med"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMra1601333","volume":"376","author":"Choueiri T.K.","year":"2017","unstructured":"Choueiri T.K.; Motzer R.J.; Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med 2017,376(4),354-366","journal-title":"N Engl J Med"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3322\/canjclin.57.2.112","volume":"57","author":"Garcia J.A.","year":"2007","unstructured":"Garcia J.A.; Rini B.I.; Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin 2007,57(2),112-125","journal-title":"CA Cancer J Clin"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1002\/cncr.22904","volume":"110","author":"Launay-Vacher V.","year":"2007","unstructured":"Launay-Vacher V.; Oudard S.; Janus N.; Gligorov J.; Pourrat X.; Rixe O.; Morere J.F.; Beuzeboc P.; Deray G.; Renal insufficiency and cancer medications (IRMA) study group. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 2007,110(6),1376-1384","journal-title":"Cancer"},{"key":"ref=43","author":"Association BOP","year":"2003","unstructured":"Association BOP; Dosage Adjustment for Cytotoxics in Hepatic and Renal Impairment. S Daniels, Guy's Available from: 2003","journal-title":"S Daniels, Guy's"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1200\/JCO.2005.03.8299","volume":"24","author":"Rahman A.","year":"2006","unstructured":"Rahman A.; White R.M.; Cytotoxic anticancer agents and renal impairment study: the challenge remains. J Clin Oncol 2006,24(4),533-536","journal-title":"J Clin Oncol"},{"key":"ref=45","first-page":"1057","volume":"19","author":"Eklund JW","year":"2005","unstructured":"Eklund JW; Trifilio S; Mulcahy MF; Chemotherapy dosing in the setting of liver dysfunction. Oncology 2005,19(8),1057-63","journal-title":"Oncology"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","volume":"145","author":"Levey A.S.","year":"2006","unstructured":"Levey A.S.; Coresh J.; Greene T.; Stevens L.A.; Zhang Y.L.; Hendriksen S.; Kusek J.W.; Van Lente F.; Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med Chronic kidney disease epidemiology collaboration2006,145(4),247-254","journal-title":"Ann Intern Med"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1681\/ASN.2009020171","volume":"20","author":"Stevens L.A.","year":"2009","unstructured":"Stevens L.A.; Levey A.S.; Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol 2009,20(11),2305-2313","journal-title":"J Am Soc Nephrol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1053\/j.ajkd.2009.03.008","volume":"54","author":"Stevens L.A.","year":"2009","unstructured":"Stevens L.A.; Nolin T.D.; Richardson M.M.; Feldman H.I.; Lewis J.B.; Rodby R.; Townsend R.; Okparavero A.; Zhang Y.L.; Schmid C.H.; Levey A.S.; Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations. Am J Kidney Dis Chronic Kidney Disease Epidemiology Collaboration2009,54(1),33-42","journal-title":"Am J Kidney Dis"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1053\/j.ajkd.2007.04.004","volume":"50","author":"Stevens L.A.","year":"2007","unstructured":"Stevens L.A.; Manzi J.; Levey A.S.; Chen J.; Deysher A.E.; Greene T.; Poggio E.D.; Schmid C.H.; Steffes M.W.; Zhang Y.L.; Van Lente F.; Coresh J.; Impact of creatinine calibration on performance of GFR estimating equations in a pooled individual patient database. Am J Kidney Dis 2007,50(1),21-35","journal-title":"Am J Kidney Dis"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"297","DOI":"10.5858\/2005-129-297-CMSOTA","volume":"129","author":"Miller W.G.","year":"2005","unstructured":"Miller W.G.; Myers G.L.; Ashwood E.R.; Killeen A.A.; Wang E.; Thienpont L.M.; Siekmann L.; Creatinine measurement: state of the art in accuracy and interlaboratory harmonization. Arch Pathol Lab Med 2005,129(3),297-304","journal-title":"Arch Pathol Lab Med"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"Levey A.S.","year":"1999","unstructured":"Levey A.S.; Bosch J.P.; Lewis J.B.; Greene T.; Rogers N.; Roth D.; A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med Modification of Diet in Renal Disease Study Group1999,130(6),461-470","journal-title":"Ann Intern Med"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMra054415","volume":"354","author":"Stevens L.A.","year":"2006","unstructured":"Stevens L.A.; Coresh J.; Greene T.; Levey A.S.; Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 2006,354(23),2473-2483","journal-title":"N Engl J Med"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1681\/ASN.2007020199","volume":"18","author":"Stevens L.A.","year":"2007","unstructured":"Stevens L.A.; Coresh J.; Feldman H.I.; Greene T.; Lash J.P.; Nelson R.G.; Rahman M.; Deysher A.E.; Zhang Y.L.; Schmid C.H.; Levey A.S.; Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol 2007,18(10),2749-2757","journal-title":"J Am Soc Nephrol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1373\/clinchem.2006.077180","volume":"53","author":"Levey A.S.","year":"2007","unstructured":"Levey A.S.; Coresh J.; Greene T.; Marsh J.; Stevens L.A.; Kusek J.W.; Van Lente F.; Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem Chronic Kidney Disease Epidemiology Collaboration2007,53(4),766-772","journal-title":"Clin Chem"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"Cockcroft D.W.","year":"1976","unstructured":"Cockcroft D.W.; Gault M.H.; Prediction of creatinine clearance from serum creatinine. Nephron 1976,16(1),31-41","journal-title":"Nephron"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1053\/j.ajkd.2005.04.023","volume":"46","author":"Poggio E.D.","year":"2005","unstructured":"Poggio E.D.; Nef P.C.; Wang X.; Greene T.; Van Lente F.; Dennis V.W.; Hall P.M.; Performance of the Cockcroft-Gault and modification of diet in renal disease equations in estimating GFR in ill hospitalized patients. Am J Kidney Dis 2005,46(2),242-252","journal-title":"Am J Kidney Dis"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"Levey A.S.","year":"2009","unstructured":"Levey A.S.; Stevens L.A.; Schmid C.H.; Zhang Y.L.; Castro A.F.; Feldman H.I.; Kusek J.W.; Eggers P.; Van Lente F.; Greene T.; Coresh J.; A new equation to estimate glomerular filtration rate. Ann Intern Med CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)2009,150(9),604-612","journal-title":"Ann Intern Med"},{"key":"ref=58","first-page":"69","volume":"32","author":"Doogue M.P.","year":"2011","unstructured":"Doogue M.P.; Polasek T.M.; Drug dosing in renal disease. Clin Biochem Rev 2011,32(2),69-73","journal-title":"Clin Biochem Rev"},{"key":"ref=59","first-page":"589","author":"Maker JH","year":"2017","unstructured":"Maker JH; Dager WE; Acute kidney injury. In: DiPiro, J.T.; Talbert, R.L.; Yee, G.C.; Matzke, G.R.; Wells, B.G.; Posey, L.M., Eds. Pharmacotherapy: A pathophysiologic approach New York: McGraw-Hill Education, 2017,589-608","journal-title":"Pharmacotherapy: A pathophysiologic approach"},{"key":"ref=60","first-page":"45","volume":"9","author":"DiPiro JT","year":"2014","unstructured":"DiPiro JT; Talbert RL; Yee GC; Matzke GR; Wells BG; Posey LM; A guide to clinically relevant drug interactions in oncology. J Oncol Pharm 2014,9(2-3),45-85","journal-title":"J Oncol Pharm"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1191\/1078155203jp107oa","volume":"9","author":"Lam M.S.","year":"2003","unstructured":"Lam M.S.; Ignoffo R.J.; A guide to clinically relevant drug interactions in oncology. J Oncol Pharm Pract 2003,9(2-3),45-85","journal-title":"J Oncol Pharm Pract"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/scipharm85010008","volume":"85","author":"Hendrayana T.","year":"2017","unstructured":"Hendrayana T.; Wilmer A.; Kurth V.; Schmidt-Wolf I.G.; Jaehde U.; Anticancer dose adjustment for patients with renal and hepatic dysfunction: from scientific evidence to clinical application. Sci Pharm 2017,85(1),8","journal-title":"Sci Pharm"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0305-7372(95)90010-1","volume":"21","author":"Kintzel P.E.","year":"1995","unstructured":"Kintzel P.E.; Dorr R.T.; Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev 1995,21(1),33-64","journal-title":"Cancer Treat Rev"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"157","DOI":"10.4103\/1658-631X.142504","volume":"2","author":"Javaid A.","year":"2014","unstructured":"Javaid A.; Munir I.; Jaffri S.A.; Qazi M.H.; Nawaz M.K.; A comparison between estimates of glomerular filtration rate using technetium-99m-diethylene-triamine-pentaacetic acid clearance and modification of diet in renal disease equation. Saudi J Med Med Sci 2014,2(3),157","journal-title":"Saudi J Med Med Sci"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0031-3955(16)32568-8","volume":"18","author":"Bricker N.S.","year":"1971","unstructured":"Bricker N.S.; Klahr S.; Lubowitz H.; Slatopolsky E.; The pathophysiology of renal insufficiency. On the functional transformations in the residual nephrons with advancing disease. Pediatr Clin North Am 1971,18(2),595-611","journal-title":"Pediatr Clin North Am"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1054\/bjoc.2000.1643","volume":"84","author":"Wright J.G.","year":"2001","unstructured":"Wright J.G.; Boddy A.V.; Highley M.; Fenwick J.; McGill A.; Calvert A.H.; Estimation of glomerular filtration rate in cancer patients. Br J Cancer 2001,84(4),452-459","journal-title":"Br J Cancer"},{"key":"ref=67","first-page":"107","volume":"50","author":"Lohr J.W.","year":"1998","unstructured":"Lohr J.W.; Willsky G.R.; Acara M.A.; Renal drug metabolism. Pharmacol Rev 1998,50(1),107-141","journal-title":"Pharmacol Rev"},{"year":"2002","author":"Glaspy J.A.","key":"ref=68","unstructured":"Glaspy J.A.; Ed.; Therapeutic options in the management of renal cell carcinoma. Seminars in oncology. Amsterdam: Elsevier 2002"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s11864-003-0037-4","volume":"4","author":"Campbell S.C.","year":"2003","unstructured":"Campbell S.C.; Flanigan R.C.; Clark J.I.; Nephrectomy in metastatic renal cell carcinoma. Curr Treat Options Oncol 2003,4(5),363-372","journal-title":"Curr Treat Options Oncol"},{"key":"ref=70","author":"Atkins MB","year":"2012","unstructured":"Atkins MB; Overview of the treatment of renal cell carcinoma. Literature review current through: Available from: 2012","journal-title":"Literature review current through:"},{"key":"ref=71","doi-asserted-by":"crossref","DOI":"10.56021\/9780801855948","author":"Buckman R.","year":"1997","unstructured":"Buckman R.; What you really need to know about cancer: A comprehensive guide for patients and their families Baltimore: Johns Hopkins University Press 1997","journal-title":"What you really need to know about cancer: A comprehensive guide for patients and their families Baltimore: Johns Hopkins University Press"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1258\/jrsm.2010.100104","volume":"103","author":"Hajjaj F.M.","year":"2010","unstructured":"Hajjaj F.M.; Salek M.S.; Basra M.K.; Finlay A.Y.; Non-clinical influences on clinical decision-making: a major challenge to evidence-based practice. J R Soc Med 2010,103(5),178-187","journal-title":"J R Soc Med"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"618","DOI":"10.6004\/jnccn.2009.0043","volume":"7","author":"Motzer R.J.","year":"2009","unstructured":"Motzer R.J.; Agarwal N.; Beard C.; Bolger G.B.; Boston B.; Carducci M.A.; Choueiri T.K.; Figlin R.A.; Fishman M.; Hancock S.L.; Hudes G.R.; Jonasch E.; Kessinger A.; Kuzel T.M.; Lange P.H.; Levine E.G.; Margolin K.A.; Michaelson M.D.; Olencki T.; Pili R.; Redman B.G.; Robertson C.N.; Schwartz L.H.; Sheinfeld J.; Wang J.; NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw 2009,7(6),618-630","journal-title":"J Natl Compr Canc Netw"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMoa003013","volume":"345","author":"Flanigan R.C.","year":"2001","unstructured":"Flanigan R.C.; Salmon S.E.; Blumenstein B.A.; Bearman S.I.; Roy V.; McGrath P.C.; Caton J.R.; Munshi N.; Crawford E.D.; Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001,345(23),1655-1659","journal-title":"N Engl J Med"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"337","DOI":"10.5489\/cuaj.909","volume":"4","author":"Chapman D.","year":"2010","unstructured":"Chapman D.; Moore R.; Klarenbach S.; Braam B.; Residual renal function after partial or radical nephrectomy for renal cell carcinoma. Can Urol Assoc J 2010,4(5),337-343","journal-title":"Can Urol Assoc J"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1734-1140(12)70862-9","volume":"64","author":"Sza\u0142ek E.","year":"2012","unstructured":"Sza\u0142ek E.; Po\u0142om W.; Karbownik A.; Grabowski T.; Konko\u0142owicz A.; Wolc A.; Matuszewski M.; Krajka K.; Grze&#x15B;kowiak E.; Effect of total and partial nephrectomy on the elimination of ciprofloxacin in humans. Pharmacol Rep 2012,64(3),673-679","journal-title":"Pharmacol Rep"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/00000542-200502000-00014","volume":"102","author":"Takizawa D.","year":"2005","unstructured":"Takizawa D.; Hiraoka H.; Goto F.; Yamamoto K.; Horiuchi R.; Human kidneys play an important role in the elimination of propofol. Anesthesiology 2005,102(2),327-330","journal-title":"Anesthesiology"},{"key":"ref=78","first-page":"1434","author":"Cutler R.","year":"1989","unstructured":"Cutler R.; Forland S.C.; Hammond P.S.J.; Pharmacokinetics of drugs and the effects of renal failure. In: Textbook of nephrology New York: Williams 1989,1434-1447","journal-title":"Textbook of nephrology New York: Williams"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/S0022-5347(17)58099-4","volume":"118","author":"Freed S.Z.","year":"1977","unstructured":"Freed S.Z.; Halperin J.P.; Gordon M.; Idiopathic regression of metastases from renal cell carcinoma. J Urol 1977,118(4),538-542","journal-title":"J Urol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/S0022-5347(17)57264-X","volume":"120","author":"O\u2019dea M.J.","year":"1978","unstructured":"O\u2019dea M.J.; Zincke H.; Utz D.C.; Bernatz P.E.; The treatment of renal cell carcinoma with solitary metastasis. J Urol 1978,120(5),540-542","journal-title":"J Urol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S0022-5347(17)45085-3","volume":"136","author":"Golimbu M.","year":"1986","unstructured":"Golimbu M.; Al-Askari S.; Tessler A.; Morales P.; Aggressive treatment of metastatic renal cancer. J Urol 1986,136(4),805-807","journal-title":"J Urol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2165\/00003088-198916060-00001","volume":"16","author":"Evans W.E.","year":"1989","unstructured":"Evans W.E.; Relling M.V.; Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinet 1989,16(6),327-336","journal-title":"Clin Pharmacokinet"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1365-2125.1995.tb05796.x","volume":"40","author":"Kivist&#xF6; K.T.","year":"1995","unstructured":"Kivist&#xF6; K.T.; Kroemer H.K.; Eichelbaum M.; The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 1995,40(6),523-530","journal-title":"Br J Clin Pharmacol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"126","DOI":"10.2165\/00003088-197601020-00004","volume":"1","author":"Dettli L.","year":"1976","unstructured":"Dettli L.; Drug dosage in renal disease. Clin Pharmacokinet 1976,1(2),126-134","journal-title":"Clin Pharmacokinet"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","volume":"17","author":"Edge S.B.","year":"2010","unstructured":"Edge S.B.; Compton C.C.; The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010,17(6),1471-4","journal-title":"Ann Surg Oncol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.2146\/ajhp080387.p1","volume":"66","author":"Cersosimo R.J.","year":"2009","unstructured":"Cersosimo R.J.; Renal cell carcinoma with an emphasis on drug therapy of advanced disease, part 1. Am J Health Syst Pharm 2009,66(17),1525-1536","journal-title":"Am J Health Syst Pharm"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1200\/JCO.2005.03.206","volume":"23","author":"McDermott D.F.","year":"2005","unstructured":"McDermott D.F.; Regan M.M.; Clark J.I.; Flaherty L.E.; Weiss G.R.; Logan T.F.; Kirkwood J.M.; Gordon M.S.; Sosman J.A.; Ernstoff M.S.; Tretter C.P.; Urba W.J.; Smith J.W.; Margolin K.A.; Mier J.W.; Gollob J.A.; Dutcher J.P.; Atkins M.B.; Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005,23(1),133-141","journal-title":"J Clin Oncol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1177\/107327480200900404","volume":"9","author":"Fishman M.","year":"2002","unstructured":"Fishman M.; Seigne J.; Immunotherapy of metastatic renal cell cancer. Cancer Contr 2002,9(4),293-304","journal-title":"Cancer Contr"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/j.eururo.2007.03.035","volume":"51","author":"Ljungberg B.","year":"2007","unstructured":"Ljungberg B.; Hanbury D.C.; Kuczyk M.A.; Merseburger A.S.; Mulders P.F.; Patard J-J.; Sinescu I.C.; Renal cell carcinoma guideline. Eur Urol European Association of Urology Guideline Group for renal cell carcinoma2007,51(6),1502-1510","journal-title":"Eur Urol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.eururo.2015.01.005","volume":"67","author":"Ljungberg B.","year":"2015","unstructured":"Ljungberg B.; Bensalah K.; Canfield S.; Dabestani S.; Hofmann F.; Hora M.; Kuczyk M.A.; Lam T.; Marconi L.; Merseburger A.S.; Mulders P.; Powles T.; Staehler M.; Volpe A.; Bex A.; EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 2015,67(5),913-924","journal-title":"Eur Urol"},{"key":"ref=91","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.eururo.2019.02.011","volume":"75","year":"2019","unstructured":"Ljungberg, B.; Albiges, L.; Abu-Ghanem, Y.; Bensalah, K.; Dabestani, S.; Fern&#xE1;ndez-Pello, S.; Giles, R.H.; Hofmann, F.; Hora, M.; Kuczyk, M.A.; Kuusk, T.; Lam, T.B.; Marconi, L.; Merseburger, A.S.; Powles, T.; Staehler, M.; Tahbaz, R.; Volpe, A.; Bex, A. Renal cell carcinoma. Eur Assoc Urol 2019,75(5),799-810","journal-title":"Eur Assoc Urol"},{"key":"ref=92","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/970315","volume":"2014","author":"Asmana Ningrum R.","year":"2014","unstructured":"Asmana Ningrum R.; Human interferon alpha-2b: a therapeutic protein for cancer treatment. Scientifica 2014,2014","journal-title":"Scientifica"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1124\/jpet.105.084145","volume":"315","author":"Arora A.","year":"2005","unstructured":"Arora A.; Scholar E.M.; Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005,315(3),971-979","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.urology.2012.10.054","volume":"81","author":"Stroup S.P.","year":"2013","unstructured":"Stroup S.P.; Raheem O.A.; Palazzi K.L.; Liss M.A.; Mehrazin R.; Kopp R.P.; Patel N.; Cohen S.A.; Park S.K.; Patterson A.L.; Kane C.J.; Millard F.; Derweesh I.H.; Does timing of cytoreductive nephrectomy impact patient survival with metastatic renal cell carcinoma in the tyrosine kinase inhibitor era? A multi-institutional study. Urology 2013,81(4),805-811","journal-title":"Urology"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3892\/etm.2014.1691","volume":"8","author":"Han X.","year":"2014","unstructured":"Han X.; Shang D.; Han T.; Xu X.; Tian Y.; Interferon-&#x3B1; enhances the susceptibility of renal cell carcinoma to rapamycin by suppressing mTOR activity. Exp Ther Med 2014,8(1),267-273","journal-title":"Exp Ther Med"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/2051-1426-2-13","volume":"2","author":"Payne R.","year":"2014","unstructured":"Payne R.; Glenn L.; Hoen H.; Richards B.; Smith J.W.; Lufkin R.; Crocenzi T.S.; Urba W.J.; Curti B.D.; Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program. J Immunother Cancer 2014,2,13","journal-title":"J Immunother Cancer"},{"year":"1976","author":"Golden S.","key":"ref=97","unstructured":"Golden S.; Horwich C.; Lokich J.; US Department of Health, Education, and Welfare, Public Health Service Chemotherapy and you; 1976"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1200\/JCO.1987.5.12.1922","volume":"5","author":"Fojo A.T.","year":"1987","unstructured":"Fojo A.T.; Shen D.W.; Mickley L.A.; Pastan I.; Gottesman M.M.; Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J Clin Oncol 1987,5(12),1922-1927","journal-title":"J Clin Oncol"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0094-0143(21)00489-4","volume":"20","author":"Yagoda A.","year":"1993","unstructured":"Yagoda A.; Petrylak D.; Thompson S.; Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 1993,20(2),303-321","journal-title":"Urol Clin North Am"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0022-5347(17)42381-0","volume":"139","author":"von Roemeling R.","year":"1988","unstructured":"von Roemeling R.; Rabatin J.T.; Fraley E.E.; Hrushesky W.J.; Progressive metastatic renal cell carcinoma controlled by continuous 5-fluoro-2-deoxyuridine infusion. J Urol 1988,139(2),259-262","journal-title":"J Urol"},{"year":"1994","author":"Bjarnason G.","key":"ref=101","unstructured":"Bjarnason G.; Hrushesky W.; Diasio R.; Harris J.; Marsh R.; Huben R.; Proc Am Soc Clin Oncol Eds.; Flat versus circadian modified 14 day infusion of FUDR for advanced renal cell cancer (RCC): a phase-III study1994"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1002\/1097-0142(19930601)71:11<3601::AID-CNCR2820711122>3.0.CO;2-#","volume":"71","author":"Wilkinson M.J.","year":"1993","unstructured":"Wilkinson M.J.; Frye J.W.; Small E.J.; Venook A.P.; Carroll P.R.; Ernest M.L.; Stagg R.J.; A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma. Cancer 1993,71(11),3601-3604","journal-title":"Cancer"},{"key":"ref=103","first-page":"42","volume":"22","author":"Yagoda A.","year":"1995","unstructured":"Yagoda A.; Abi-Rached B.; Petrylak D.; Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 1995,22(1),42-60","journal-title":"Semin Oncol"},{"key":"ref=104","first-page":"1139","author":"Linehan W.M.","year":"2005","unstructured":"Linehan W.M.; Cancer, Principles and Practice of Oncology Cancer of the genitourinary system. In: DeVita, V.T.; Hellman, S.; Rosenberg, S.A. 2005,1139-1267","journal-title":"Cancer, Principles and Practice of Oncology"},{"journal-title":"Annals Of Oncology","year":"1998","key":"ref=105","unstructured":"Annals Of Oncology A phase I trial of continuous infusion 5-fluorouracil and weekly gemcitabine: Updated results of an active combination for renal cell, hepatocellular and colon carcinoma. In: Mani, S.; Gordon, G.; Vogelzang, N.; Bertucci, D.; Schilsky, R.; Stadler, W., EdsNetherlands: Kluwer Academic Publ. 1998"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.ygyno.2014.01.015","volume":"132","author":"Fleming G.F.","year":"2014","unstructured":"Fleming G.F.; Filiaci V.L.; Marzullo B.; Zaino R.J.; Davidson S.A.; Pearl M.; Makker V.; Burke J.J.; Zweizig S.L.; Van Le L.; Hanjani P.; Downey G.; Walker J.L.; Reyes H.D.; Leslie K.K.; Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study. Gynecol Oncol 2014,132(3),585-592","journal-title":"Gynecol Oncol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1056\/NEJM199609193351207","volume":"335","author":"Motzer R.J.","year":"1996","unstructured":"Motzer R.J.; Bander N.H.; Nanus D.M.; Renal-cell carcinoma. N Engl J Med 1996,335(12),865-875","journal-title":"N Engl J Med"},{"key":"ref=108","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","volume":"342","year":"2013","unstructured":"Couzin-Frankel J. Cancer immunotherapy. Science 2013,342(6165),1432-1433","journal-title":"Science"},{"journal-title":"The Merck manual of diagnosis and therapy","year":"1899","key":"ref=109","unstructured":"Merck, Co, Dohme, S.M. The Merck manual of diagnosis and therapy Amsterdam: Elsevier, 1899"},{"key":"ref=110","first-page":"940","volume":"43","author":"Quesada J.R.","year":"1983","unstructured":"Quesada J.R.; Swanson D.A.; Trindade A.; Gutterman J.U.; Renal cell carcinoma: antitumor effects of leukocyte interferon. Cancer Res 1983,43(2),940-947","journal-title":"Cancer Res"},{"key":"ref=111","first-page":"154","volume":"26","author":"McCarthy E.F.","year":"2006","unstructured":"McCarthy E.F.; The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J 2006,26,154-158","journal-title":"Iowa Orthop J"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1073\/pnas.91.4.1198","volume":"91","author":"Gutterman J.U.","year":"1994","unstructured":"Gutterman J.U.; Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci USA 1994,91(4),1198-1205","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1200\/JCO.1999.17.9.2859","volume":"17","author":"Pyrh&#xF6;nen S.","year":"1999","unstructured":"Pyrh&#xF6;nen S.; Salminen E.; Ruutu M.; Lehtonen T.; Nurmi M.; Tammela T.; Juusela H.; Rintala E.; Hietanen P.; Kellokumpu-Lehtinen P.L.; Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999,17(9),2859-2867","journal-title":"J Clin Oncol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1200\/JCO.1993.11.7.1368","volume":"11","author":"Minasian L.M.","year":"1993","unstructured":"Minasian L.M.; Motzer R.J.; Gluck L.; Mazumdar M.; Vlamis V.; Krown S.E.; Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 1993,11(7),1368-1375","journal-title":"J Clin Oncol"},{"year":"1996","author":"Pyrhonen S.","key":"ref=115","unstructured":"Pyrhonen S.; Salminen E.; Lehtonen T.; Eds.; Recombinant interferon alfa-2a with vinblastine vs. vinblastine alone in advanced renal cell carcinoma. A phase III study Proc Am Soc Clin Oncol 1996"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1056\/NEJM199804303381804","volume":"338","author":"Gleave M.E.","year":"1998","unstructured":"Gleave M.E.; Elhilali M.; Fradet Y.; Davis I.; Venner P.; Saad F.; Klotz L.H.; Moore M.J.; Paton V.; Bajamonde A.; Interferon gamma-1b compared with placebo in metastatic renal- cell carcinoma. N Engl J Med Canadian Urologic Oncology Group1998,338(18),1265-1271","journal-title":"N Engl J Med"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1200\/JCO.1993.11.4.661","volume":"11","author":"Atkins M.B.","year":"1993","unstructured":"Atkins M.B.; Sparano J.; Fisher R.I.; Weiss G.R.; Margolin K.A.; Fink K.I.; Rubinstein L.; Louie A.; Mier J.W.; Gucalp R.; Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol 1993,11(4),661-670","journal-title":"J Clin Oncol"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1200\/JCO.1998.16.5.1820","volume":"16","author":"Stadler W.M.","year":"1998","unstructured":"Stadler W.M.; Kuzel T.; Dumas M.; Vogelzang N.J.; Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma. J Clin Oncol 1998,16(5),1820-1825","journal-title":"J Clin Oncol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1200\/JCO.1998.16.7.2505","volume":"16","author":"Tourani J-M.","year":"1998","unstructured":"Tourani J-M.; Pfister C.; Berdah J-F.; Benhammouda A.; Salze P.; Monnier A.; Paule B.; Guillet P.; Chretien Y.; Brewer Y.; Di Palma M.; Untereiner M.; Malaurie E.; Tadrist Z.; Pavlovitch J.M.; Hauteville D.; Mejean A.; Azagury M.; Mayeur D.; Lucas V.; Krakowski I.; Larregain- Fournier D.; Abourachid H.; Andrieu J.M.; Chastang C.; Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. J Clin Oncol Subcutaneous Administration Propeukin Program Cooperative Group1998,16(7),2505-2513","journal-title":"J Clin Oncol"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1056\/NEJM199804303381805","volume":"338","author":"Negrier S.","year":"1998","unstructured":"Negrier S.; Escudier B.; Lasset C.; Douillard J-Y.; Savary J.; Chevreau C.; Ravaud A.; Mercatello A.; Peny J.; Mousseau M.; Philip T.; Tursz T.; Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Fran&#xE7;ais d\u2019Immunoth&#xE9;rapie. N Engl J Med 1998,338(18),1272-1278","journal-title":"N Engl J Med"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/bjc.1998.218","volume":"77","author":"Henriksson R.","year":"1998","unstructured":"Henriksson R.; Nilsson S.; Colleen S.; Wers&#xE4;ll P.; Helsing M.; Zimmerman R.; Engman K.; Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, &#x3B1;-interferon (leucocyte) and tamoxifen. Br J Cancer 1998,77(8),1311-1317","journal-title":"Br J Cancer"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","volume":"313","author":"Rosenberg S.A.","year":"1985","unstructured":"Rosenberg S.A.; Lotze M.T.; Muul L.M.; Leitman S.; Chang A.E.; Ettinghausen S.E.; Matory Y.L.; Skibber J.M.; Shiloni E.; Vetto J.T.; Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985,313(23),1485-1492","journal-title":"N Engl J Med"},{"key":"ref=123","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4049\/jimmunol.134.1.157","volume":"134","author":"Lotze M.T.","year":"1985","unstructured":"Lotze M.T.; Frana L.W.; Sharrow S.O.; Robb R.J.; Rosenberg S.A.; In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Immunol 1985,134(1),157-166","journal-title":"J Immunol"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1001\/jama.1986.03380220083027","volume":"256","author":"Lotze M.T.","year":"1986","unstructured":"Lotze M.T.; Chang A.E.; Seipp C.A.; Simpson C.; Vetto J.T.; Rosenberg S.A.; High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. JAMA 1986,256(22),3117-3124","journal-title":"JAMA"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1200\/JCO.1992.10.2.180","volume":"10","author":"Rosenberg S.A.","year":"1992","unstructured":"Rosenberg S.A.; Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer. J Clin Oncol 1992,10(2),180-199","journal-title":"J Clin Oncol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1038\/sj.bjc.6601709","volume":"90","author":"Geertsen P.F.","year":"2004","unstructured":"Geertsen P.F.; Gore M.E.; Negrier S.; Tourani J.M.; von der Maase H.; Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma. Br J Cancer 2004,90(6),1156-1162","journal-title":"Br J Cancer"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1002\/cncr.23851","volume":"113","author":"Belldegrun A.S.","year":"2008","unstructured":"Belldegrun A.S.; Klatte T.; Shuch B.; LaRochelle J.C.; Miller D.C.; Said J.W.; Riggs S.B.; Zomorodian N.; Kabbinavar F.F.; Dekernion J.B.; Pantuck A.J.; Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies. Cancer 2008,113(9),2457-2463","journal-title":"Cancer"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1200\/JCO.1994.12.8.1572","volume":"12","author":"Yang J.C.","year":"1994","unstructured":"Yang J.C.; Topalian S.L.; Parkinson D.; Schwartzentruber D.J.; Weber J.S.; Ettinghausen S.E.; White D.E.; Steinberg S.M.; Cole D.J.; Kim H.I.; Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol 1994,12(8),1572-1576","journal-title":"J Clin Oncol"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","volume":"13","author":"Fyfe G.","year":"1995","unstructured":"Fyfe G.; Fisher R.I.; Rosenberg S.A.; Sznol M.; Parkinson D.R.; Louie A.C.; Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995,13(3),688-696","journal-title":"J Clin Oncol"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"817","DOI":"10.7326\/0003-4819-106-6-817","volume":"106","author":"Belldegrun A.","year":"1987","unstructured":"Belldegrun A.; Webb D.E.; Austin H.A.; Steinberg S.M.; White D.E.; Linehan W.M.; Rosenberg S.A.; Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer. Ann Intern Med 1987,106(6),817-822","journal-title":"Ann Intern Med"},{"year":"2008","key":"ref=131","unstructured":"131. American Cancer Society. Cancer facts"},{"journal-title":"IARC handbooks of cancer prevention: The Agency","year":"2002","key":"ref=132","unstructured":"Cancer IAfRo. IARC handbooks of cancer prevention: The Agency Available from: 2002"},{"key":"ref=133","first-page":"924","volume":"32","author":"Ma\u0142yszko J.","year":"2017","unstructured":"Ma\u0142yszko J.; Koz\u0142owska K.; Koz\u0142owski L.; Ma\u0142yszko J.; Nephrotoxicity of anticancer treatment. Nephrol Dial Transplant 2017,32(6),924-936","journal-title":"Nephrol Dial Transplant"},{"key":"ref=134","first-page":"157","volume":"3","author":"Dutcher J.P.","year":"1997","unstructured":"Dutcher J.P.; Fisher R.I.; Weiss G.; Aronson F.; Margolin K.; Louie A.; Mier J.; Caliendo G.; Sosman J.A.; Eckardt J.R.; Ernest M.L.; Doroshow J.; Atkins M.; Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am 1997,3(3),157-162","journal-title":"Cancer J Sci Am"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.cell.2015.03.045","volume":"161","author":"Topalian S.L.","year":"2015","unstructured":"Topalian S.L.; Wolchok J.D.; Chan T.A.; Mellman I.; Palucka K.; Banchereau J.; Rosenberg S.A.; Dane Wittrup K.; Immunotherapy: the path to win the war on cancer? Cell 2015,161(2),185-186","journal-title":"Cell"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"4828","DOI":"10.1200\/JCO.2011.38.0899","volume":"29","author":"Topalian S.L.","year":"2011","unstructured":"Topalian S.L.; Weiner G.J.; Pardoll D.M.; Cancer immunotherapy comes of age. J Clin Oncol 2011,29(36),4828-4836","journal-title":"J Clin Oncol"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"5472","DOI":"10.1158\/1078-0432.CCR-04-2658","volume":"11","author":"Clark J.W.","year":"2005","unstructured":"Clark J.W.; Eder J.P.; Ryan D.; Lathia C.; Lenz H-J.; Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005,11(15),5472-5480","journal-title":"Clin Cancer Res"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","volume":"25","author":"Chow L.Q.","year":"2007","unstructured":"Chow L.Q.; Eckhardt S.G.; Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007,25(7),884-896","journal-title":"J Clin Oncol"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nm0904-887","volume":"10","author":"Pardoll D.","year":"2004","unstructured":"Pardoll D.; Allison J.; Cancer immunotherapy: breaking the barriers to harvest the crop. Nat Med 2004,10(9),887-892","journal-title":"Nat Med"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1038\/bjc.2014.244","volume":"110","author":"Escudier B.","year":"2014","unstructured":"Escudier B.; Michaelson M.D.; Motzer R.J.; Hutson T.E.; Clark J.I.; Lim H.Y.; Porfiri E.; Zalewski P.; Kannourakis G.; Staehler M.; Tarazi J.; Rosbrook B.; Cisar L.; Hariharan S.; Kim S.; Rini B.I.; Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. Br J Cancer 2014,110(12),2821-2828","journal-title":"Br J Cancer"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","volume":"370","author":"Escudier B.","year":"2007","unstructured":"Escudier B.; Pluzanska A.; Koralewski P.; Ravaud A.; Bracarda S.; Szczylik C.; Chevreau C.; Filipek M.; Melichar B.; Bajetta E.; Gorbunova V.; Bay J.O.; Bodrogi I.; Jagiello-Gruszfeld A.; Moore N.; Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet AVOREN Trial investigators2007,370(9605),2103-2111","journal-title":"Lancet"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"Hudes G.","year":"2007","unstructured":"Hudes G.; Carducci M.; Tomczak P.; Dutcher J.; Figlin R.; Kapoor A.; Staroslawska E.; Sosman J.; McDermott D.; Bodrogi I.; Kovacevic Z.; Lesovoy V.; Schmidt-Wolf I.G.; Barbarash O.; Gokmen E.; O\u2019Toole T.; Lustgarten S.; Moore L.; Motzer R.J.; Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med Global ARCC Trial2007,356(22),2271-2281","journal-title":"N Engl J Med"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"Motzer R.J.","year":"2008","unstructured":"Motzer R.J.; Escudier B.; Oudard S.; Hutson T.E.; Porta C.; Bracarda S.; Gr&#xFC;nwald V.; Thompson J.A.; Figlin R.A.; Hollaender N.; Urbanowitz G.; Berg W.J.; Kay A.; Lebwohl D.; Ravaud A.; Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet RECORD-1 Study Group2008,372(9637),449-456","journal-title":"Lancet"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(03)13643-4","volume":"361","author":"Lonser R.R.","year":"2003","unstructured":"Lonser R.R.; Glenn G.M.; Walther M.; Chew E.Y.; Libutti S.K.; Linehan W.M.; Oldfield E.H.; von Hippel-Lindau disease. Lancet 2003,361(9374),2059-2067","journal-title":"Lancet"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/ncpuro0179","volume":"2","author":"Grubb R.L.","year":"2005","unstructured":"Grubb R.L.; Choyke P.L.; Pinto P.A.; Linehan W.M.; Walther M.M.; Management of von Hippel-Lindau-associated kidney cancer. Nat Clin Pract Urol 2005,2(5),248-255","journal-title":"Nat Clin Pract Urol"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1093\/qjmed\/77.2.1151","volume":"77","author":"Maher E.R.","year":"1990","unstructured":"Maher E.R.; Yates J.R.; Harries R.; Benjamin C.; Harris R.; Moore A.T.; Ferguson-Smith M.A.; Clinical features and natural history of von Hippel-Lindau disease. Q J Med 1990,77(283),1151-1163","journal-title":"Q J Med"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nrc3844","volume":"15","author":"Gossage L.","year":"2015","unstructured":"Gossage L.; Eisen T.; Maher E.R.; VHL, the story of a tumour suppressor gene. Nat Rev Cancer 2015,15(1),55-64","journal-title":"Nat Rev Cancer"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/20459","volume":"399","author":"Maxwell P.H.","year":"1999","unstructured":"Maxwell P.H.; Wiesener M.S.; Chang G.W.; Clifford S.C.; Vaux E.C.; Cockman M.E.; Wykoff C.C.; Pugh C.W.; Maher E.R.; Ratcliffe P.J.; The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999,399(6733),271-275","journal-title":"Nature"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/ki.2009.296","volume":"76","author":"Clark P.E.","year":"2009","unstructured":"Clark P.E.; The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. Kidney Int 2009,76(9),939-945","journal-title":"Kidney Int"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.1200\/JCO.2002.10.088","volume":"20","author":"Dvorak H.F.","year":"2002","unstructured":"Dvorak H.F.; Vascular permeability factor\/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002,20(21),4368-4380","journal-title":"J Clin Oncol"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nm1337","volume":"12","author":"Thomas G.V.","year":"2006","unstructured":"Thomas G.V.; Tran C.; Mellinghoff I.K.; Welsbie D.S.; Chan E.; Fueger B.; Czernin J.; Sawyers C.L.; Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006,12(1),122-127","journal-title":"Nat Med"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"Demetri G.D.","year":"2002","unstructured":"Demetri G.D.; von Mehren M.; Blanke C.D.; Van den Abbeele A.D.; Eisenberg B.; Roberts P.J.; Heinrich M.C.; Tuveson D.A.; Singer S.; Janicek M.; Fletcher J.A.; Silverman S.G.; Silberman S.L.; Capdeville R.; Kiese B.; Peng B.; Dimitrijevic S.; Druker B.J.; Corless C.; Fletcher C.D.; Joensuu H.; Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002,347(7),472-480","journal-title":"N Engl J Med"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S0092-8674(00)00114-8","volume":"103","author":"Schlessinger J.","year":"2000","unstructured":"Schlessinger J.; Cell signaling by receptor tyrosine kinases. Cell 2000,103(2),211-225","journal-title":"Cell"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1093\/emboj\/19.13.3159","volume":"19","author":"Olayioye M.A.","year":"2000","unstructured":"Olayioye M.A.; Neve R.M.; Lane H.A.; Hynes N.E.; The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000,19(13),3159-3167","journal-title":"EMBO J"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1677\/erc.0.0080011","volume":"8","author":"Prenzel N.","year":"2001","unstructured":"Prenzel N.; Fischer O.M.; Streit S.; Hart S.; Ullrich A.; The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 2001,8(1),11-31","journal-title":"Endocr Relat Cancer"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0093-7754(01)90284-2","volume":"28","author":"Slichenmyer W.J.","year":"2001","unstructured":"Slichenmyer W.J.; Fry D.W.; Anticancer therapy targeting the erbB family of receptor tyrosine kinases. Semin Oncol 2001,28(5)(Suppl. 16),67-79","journal-title":"Semin Oncol"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/35077225","volume":"411","author":"Blume-Jensen P.","year":"2001","unstructured":"Blume-Jensen P.; Hunter T.; Oncogenic kinase signalling. Nature 2001,411(6835),355-365","journal-title":"Nature"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s40265-013-0043-1","volume":"73","author":"Escudier B.","year":"2013","unstructured":"Escudier B.; Albiges L.; Sonpavde G.; Optimal management of metastatic renal cell carcinoma: current status. Drugs 2013,73(5),427-438","journal-title":"Drugs"},{"author":"Powles T.","key":"ref=159","unstructured":"Powles T.; Ed.; Sequencing systemic therapies in advanced RCC: is there a best strategy? 2013."},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"831","DOI":"10.2217\/fon.13.58","volume":"9","author":"Sabbatini R.","year":"2013","unstructured":"Sabbatini R.; Ortega C.; Procopio G.; Masini C.; Galligioni E.; Porta C.; Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor. Future Oncol 2013,9(6),831-843","journal-title":"Future Oncol"}],"container-title":["Current Drug Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/187905","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/187905\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/187905","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T07:13:39Z","timestamp":1697094819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/187905\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":160,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389200221666201112112707","relation":{},"ISSN":["1389-2002"],"issn-type":[{"type":"print","value":"1389-2002"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-06-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}